[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attention-deficit\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attention-deficit":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,72,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100647003","diagnostic-accuracy-and-safety-of-the-attention-deficithyperactivity-disorder-auxiliary-evaluation-system-ahef-in-chinese-children-aged-6-to-12-100647003",false,"NCT07683156","Diagnostic Accuracy and Safety of the Attention-Deficit\u002FHyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12","A Multicenter Prospective Clinical Study: Evaluating the Diagnostic Efficacy and Safety of the Attention-Deficit\u002FHyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12","Inclusion Criteria:\n\n* Age range: 6-12 years old, gender not restricted;\n* For children presenting for an initial ADHD diagnostic visit: presenting with common symptoms of ADHD such as inattention, hyperactivity, impulsivity, learning difficulties, behavioral problems, etc., and requiring a comprehensive assessment to confirm the diagnosis; Normal children: showing no obvious abnormal manifestations in family and school life, such as parents or teachers' initial assessment indicating basic health and normal neurodevelopmental behavioral performance, with no relevant medical history;\n* Normal intelligence (Wechsler Intelligence Scale for Children IQ ≥ 85);\n* The patient and\u002For their guardian have agreed to participate in the study and have signed the informed consent form; for participants aged 8 and above, a pediatric informed consent form must also be signed.\n\nExclusion Criteria:\n\n* Suffering from mental disorders or other neurodevelopmental disorders (such as autism spectrum disorder, schizophrenia, bipolar disorder, depressive disorder, tic disorder, reading disorder, anxiety disorders or stress-related disorders that still meet the diagnostic criteria within the last 6 months), neurological diseases such as epilepsy, and brain organic diseases, etc.;\n* Acute stage of respiratory, digestive, circulatory, urinary, immune, endocrine system diseases or acute episodes of chronic diseases (such as common acute symptoms like fever, breathing difficulties, diarrhea, etc.) and those judged by the investigator to potentially affect the research results;\n* Hearing impairment with corrected hearing not within the normal range, visual impairment with corrected vision not within the normal range, visual impairments such as color blindness, and other visual or hearing problems affecting software users;\n* Those previously diagnosed with ADHD or suspected ADHD;\n* Those who have received, are receiving, or plan to receive any psychological treatment for ADHD or non-drug treatment for the nervous system, or other cognitive, psychological-related behavioral intervention treatments in the past 6 months;\n* Those who have received neurological drug treatment (especially ADHD treatment drugs) and are still within 5 half-lives after the last medication at the time of enrollment; those who are currently receiving or plan to receive any ADHD or neurological drug treatment during the trial;\n* Those who have had gaming addiction in the past;\n* Motor conditions (e.g., hand dysfunction) reported by family members or observed by the investigator that would interfere with the trial procedures.\n* Those who have had suicidal thoughts or the investigator judges that they have suicidal impulses, non-suicidal self-harm impulses;\n* Those who are participating in other clinical trials or have not completed other trials within 1 month;\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.",true,"ALL","6 Years","12 Years",{"count":21,"type":22},570,"ESTIMATED","OBSERVATIONAL","This clinical trial aims to evaluate the diagnostic efficacy and safety of the Attention Deficit Hyperactivity Disorder Assessment System (AHEF) in children aged 6 to 12 in China, while ensuring the safety of the subjects and maintaining the scientific integrity of the clinical trial.",[26,27],"Attention-Deficit","Hyperactivity Disorder","NOT_YET_RECRUITING","2026-07-27",{"date":31,"type":32},"2026-07-29","ACTUAL",{"date":34,"type":22},"2026-07-31",{"date":36,"type":22},"2027-04-04",{"name":38,"class":39},"Chongqing Jinsaixing Medical Technology Co., Ltd","INDUSTRY",8,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100500932","neurocognitive-effects-of-non-invasive-near-infrared-light-stimulation-100500932","NCT05802680","Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation","Inclusion Criteria:\n\n* 18 years of age or older\n\nExclusion Criteria:\n\n* None","18 Years",{"count":49,"type":22},500,"INTERVENTIONAL",[52],"NA","Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe and non-invasive modality for activation of the prefrontal cortex. tPBM in healthy adults has been shown to augment brain oxygenation, cognition, and mood. The cognition-enhancing effect of tPBM on sustained attention in adults with ADHD remains unstudied. The investigators will evaluate whether tPBM administration to adults with and without ADHD can improve their attention. Each participant will be screened for eighteen criteria based on the Diagnostic and Statistical Manual (DSM-IV, text revised), using the validated instrument Adult ADHD Self-Report Scale (ASRS-v1.1). Blinded participants will be randomized into (I) Active-tPBM or (II) Sham-tPBM groups. After undergoing an 8-minute administration of Sham or 1064 nm tPBM to the lateral and medial right prefrontal cortex, each participant will complete a 14-minute, computer-based Conner's continuous performance task-3 (CPT-3). The investigators will examine whether adults with and without ADHD who receive Active-tPBM improve in measures of inattention, impulsivity, sustained attention, or vigilance compared to the Sham-tPBM group. Cognitive assessments of attention like the CPT-3 may evaluate the efficacy of tPBM to increase cortical metabolism in healthy adults and individuals with conditions like ADHD. The investigators anticipate their investigation will be a starting point for more sophisticated studies that focus on the implications of tPBM on cognition.",[55,56,57,58,59],"Attention Deficit Hyperactivity Disorder","Attention Difficulties","Attention Deficit","Cognitive Deficit","Wellness","RECRUITING","2026-06-17",{"date":63,"type":32},"2026-06-22",{"date":65,"type":32},"2022-02-09",{"date":67,"type":22},"2027-02-01",{"name":69,"class":70},"Francisco Gonzalez-Lima, PhD","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":50,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":71},"100446933","feasibility-and-efficacy-of-attentional-control-training-in-sickle-cell-disease-100446933","NCT05099874","Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease","ACT","Inclusion Criteria:\n\n* diagnosis of SCD\n* ages 8-16 years\n* maintained on monthly blood transfusions consistently for at least 3 months.\n* patients will be proceed to the intervention phase only if they have a T-score \\> 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score \\> 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).\n\nExclusion Criteria:\n\n* estimated Intelligence Quotient \\\u003C 70\n* motor, visual, or auditory impairment that prevents computer use\n* known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training\n* history of photosensitive seizures\n* insufficient English fluency.","8 Years","16 Years",{"count":82,"type":22},20,[52],"Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.",[86,57,87],"Sickle Cell Disease","Cognitive Deficit in Attention","2025-01-08",{"date":90,"type":32},"2025-01-10",{"date":92,"type":32},"2022-12-20",{"date":94,"type":22},"2025-12",{"name":96,"class":70},"Children's National Research Institute",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":47,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":50,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100510301","neurofeedback-trainings-efficiency-for-attentionnal-performances-100510301","NCT05924659","Neurofeedback Training's Efficiency for Attentionnal Performances","Evaluation of Neurofeedback Training's Efficiency for the Optimization of Attentionnal Performances","ENOCA","Inclusion Criteria:\n\n* healthy male or female volunteers\n* aged between 18 yo and 50 yo.\n\nExclusion Criteria:\n\n* any pathological issues,\n* previous traumatic brain and\u002For auditive injuries,\n* volunteers having already experienced NFB trainings,\n* high tobacco consumers,\n* volunteers refusing genotyping.","59 Years",{"count":107,"type":22},108,[52],"This randomised, double bling and controled study aim to evaluate the performance of a neurofeedback training on attentional capabilities, in comparison to placebo. We hypothesize 1) that an electroencephalographic (EEG) based neurofeedback training may improve attentional performances of healthy subjects, and 2) inter-individual variability might be explained by factors such as body awarness, sleep parameters and genetics of individuals.",[111],"Attention-deficit","2024-06-19",{"date":114,"type":32},"2024-06-24",{"date":116,"type":32},"2023-06-25",{"date":118,"type":22},"2024-08-01",{"name":120,"class":121},"Institut de Recherche Biomedicale des Armees","OTHER_GOV",2]